Tianshuang Xia

Mrs. Tianshuang Xia

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
TJTao Jiang
Tao Jiang
TXTianshuang Xia
Tianshuang Xia
FQFangliang Qiao
Fangliang Qiao
NWNani Wang
Nani Wang
YJYiping Jiang
Yiping Jiang
HXHailiang Xin
Hailiang Xin
Bones serve mechanical and defensive functions, as well as regulating the balance of calcium ions and housing bone marrow.. The qualities of bones do not remain constant. Instead, they fluctuate throughout life, with functions increasing in some situations while deteriorating in others. The synchronization of osteoblast-mediated bone formation and osteoclast-mediated bone resorption is critical for maintaining bone mass and microstructure integrity in a steady state. This equilibrium, however, can be disrupted by a variety of bone pathologies. Excessive osteoclast differentiation can result in osteoporosis, Paget’s disease, osteolytic bone metastases, and rheumatoid arthritis, all of which can adversely affect people’s health. Osteoclast differentiation is regulated by transcription factors NFATc1, MITF, C/EBPα, PU.1, NF-κB, and c-Fos. The transcriptional activity of osteoclasts is largely influenced by developmental and environmental signals with the involvement of co-factors, RNAs, epigenetics, systemic factors, and the microenvironment. In this paper, we review these themes in regard to transcriptional regulation in osteoclastogenesis.

1 January 2023 in The American Journal of Chinese Medicine
Verified
Journal Article
Closed access
KLKun Li
Kun Li
YJYiping Jiang
Yiping Jiang
NWNani Wang
Nani Wang
LLLiyong Lai
Liyong Lai
SXShengyan Xu
Shengyan Xu
XHXin Hailiang
Xin Hailiang

30 March 2022 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PDF file
TXTianshuang Xia
Tianshuang Xia
XLXiaoyan Liu
Xiaoyan Liu
NWNani Wang
Nani Wang
YJYiping Jiang
Yiping Jiang
HBHuanhuan Bai
Huanhuan Bai
XHXin Hailiang
Xin Hailiang
Xanthohumol (XAN), a natural isoflavone from Humulus lupulus L., possesses biological activities on relieving oxidative stress and osteoporosis (OP). This study aimed to evaluate the antioxidative and osteoprotective effect of XAN on Aβ-injured osteoblasts, and explore its underlying mechanism. Osteoblasts were pretreated with XAN followed by stimulation with Aβ1–42. Cell proliferation, ALP activity, bone mineralization and bone formation index were measured. Apoptosis and reactive oxygen species (ROS) were analysed with flow cytometer. PI3K inhibitor LY294002 or siRNA-Nrf2 was added and transfected in osteoblasts, to further confirm whether the pathway participated in the regulation of XAN-induced cytoprotection. XAN markedly improved the proliferation, differentiation and mineralization of Aβ-injured osteoblasts. Additionally, XAN reduced cell apoptosis rate and ROS level, and increased the expression of p-AKT, Nrf2, NQO1, HO-1 and SOD-2. More importantly, LY294002 or siNrf2 abolished the beneficial effect of XAN on osteoblasts activity and decreased the PI3K expression and inhibited its downstream proteins, indicating XAN activated PI3K/AKT/Nrf2 pathway in Aβ-injured osteoblasts. It was the first time to reveal the antioxidative and osteoprotective effect of XAN through regulating PI3K/AKT/Nrf2 pathway in Aβ-injured osteoblasts, which provides reference for the clinical application of XAN in the prevention and treatment of OP.

18 June 2025 in Phytotherapy Research
Verified
Journal Article
Closed access
WFWeiqing Fan
Weiqing Fan
TXTianshuang Xia
Tianshuang Xia
YJYiping Jiang
Yiping Jiang
KLKun Li
Kun Li
JHJianyong Han
Jianyong Han
XHXin Hailiang
Xin Hailiang

6 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
TXTianshuang Xia
Tianshuang Xia
JZJiabao Zhang
Jiabao Zhang
YGYunxiang Guo
Yunxiang Guo
YJYiping Jiang
Yiping Jiang
FQFangliang Qiao
Fangliang Qiao
XHXin Hailiang
Xin Hailiang
As aging progresses, β-amyloid (Aβ) deposition and the resulting oxidative damage are key causes of aging diseases such as senior osteoporosis (SOP). Humulus lupulus L. (hops) is an important medicinal plant widely used in the food, beverage and pharmaceutical industries due to its strong antioxidant ability. In this study, APP/PS1 mutated transgenic mice and Aβ-injured osteoblasts were used to evaluate the protective effects of hops extracts (HLE) on SOP. Mice learning and memory levels were assessed by the Morris water maze. Mice femurs were prepared for bone micro-structures and immunohistochemistry experiments. The deposition of Aβ in the hippocampus, cortex and femurs were determined by Congo red staining. Moreover, protein expressions related to antioxidant pathways were evaluated by Western blotting. It was found that HLE markedly improved learning abilities and ameliorated memory impairment of APP/PS1 mice, as well as regulated antioxidant enzymes and bone metabolism proteins in mice serum. Micro-CT tests indicated that HLE enhanced BMD and improved micro-architectural parameters of mice femur. More importantly, it was discovered that HLE significantly reduced Aβ deposition both in the brain and femur. Further in vitro results showed HLE increased the bone mineralization nodule and reduced the ROS level of Aβ-injured osteoblasts. Additionally, HLE increased the expression of antioxidant related proteins Nrf2, HO-1, NQO1, FoxO1 and SOD-2. These results indicated that Humulus lupulus L. extract could protect against senior osteoporosis through inhibiting Aβ deposition and oxidative stress, which provides a reference for the clinical application of hops in the prevention and treatment of SOP.

1 June 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
WXWeifan Xu
Weifan Xu
YJYiping Jiang
Yiping Jiang
NWNani Wang
Nani Wang
HBHuanhuan Bai
Huanhuan Bai
SXShengyan Xu
Shengyan Xu
XHXin Hailiang
Xin Hailiang
Alzheimer’s disease (AD) and osteoporosis (OP) are progressive degenerative diseases caused by multiple factors, placing a huge burden on the world. Much evidence indicates that OP is a common complication in AD patients. In addition, there is also evidence to show that patients with OP have a higher risk of AD than those without OP. This suggests that the association between the two diseases may be due to a pathophysiological link rather than one disease causing the other. Several in vitro and in vivo studies have also proved their common pathogenesis. Based on the theory of traditional Chinese medicine, some classic and specific natural Chinese medicines are widely used to effectively treat AD and OP. Current evidence also shows that these treatments can ameliorate both brain damage and bone metabolism disorder and further alleviate AD complicated with OP. These valuable therapies might provide effective and safe alternatives to major pharmacological strategies.